SIAP
NTLA icon

Sterling Investment Advisors (Pennsylvania)’s Intellia Therapeutics NTLA Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-300
Closed -$22K – 595
2022
Q1 		$22K Hold
300
– – 0.01% 351
2021
Q4 		$35K Hold
300
– – 0.01% 293
2021
Q3 		$40K Hold
300
– – 0.01% 275
2021
Q2 		$49K Buy
+300
New +$23.4K 0.01% 258

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s NTLA Position: Q2 2022 in Review

Sterling Investment Advisors (Pennsylvania) sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 300 shares — an estimated $22K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in NTLA in Q2 2021 and held it in 4 quarters. The position peaked at $49K in Q2 2021. 300 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Sterling Investment Advisors (Pennsylvania) reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sterling Investment Advisors (Pennsylvania) sold 300 Intellia Therapeutics shares in Q2 2022, an estimated $22K.
  • Sterling Investment Advisors (Pennsylvania) first reported a position in Intellia Therapeutics in Q2 2021 and held it in 4 quarters.
  • Sterling Investment Advisors (Pennsylvania)'s Intellia Therapeutics position peaked at $49K in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q2 2022, filed 5 Aug 2022.